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We report here the results of the analytical validation of assays that measure HER2 total protein (H2T) and HER2 homodimer
(H2D) expression in Formalin Fixed Paraﬃn Embedded (FFPE) breast cancer tumors as well as cell line controls. The assays are
based on the VeraTag technology platform and are commercially available through a central CAP-accredited clinical reference
laboratory. The accuracy of H2T measurements spans a broad dynamic range (2-3 logs) as evaluated by comparison with cross-
validating technologies. The measurement of H2T expression demonstrates a sensitivity that is approximately 7–10 times greater
than conventional immunohistochemistry (IHC) (HercepTest). The HERmark assay is a quantitative assay that sensitively and
reproduciblymeasurescontinuousH2TandH2Dproteinexpressionlevelsandthereforemayhavethepotentialtostratifypatients
more accurately with respect to response to HER2-targeted therapies than current methods which rely on semiquantitative protein
measurements (IHC) or on indirect assessments of gene ampliﬁcation (FISH).
1.Introduction
T h eh u m a ne p i d e r m a lg r o w t hf a c t o rr e c e p t o r2( H E R 2 )
is a transmembrane protein tyrosine kinase receptor that
is important in initiating signal transduction pathways
in normal and abnormal cells [1–5]. HER2 is overex-
pressed/ampliﬁed in approximately 15%–30% of human
breast tumors and is a biomarker of poor prognosis in
patientsdemonstratingeitherhighproteinlevelsand/orgene
ampliﬁcation on chromosome 17 [4, 6, 7]. For this reason,
HER2 testing is recommended for all newly diagnosed breast
cancer patients for the selection of individuals that may
beneﬁt from treatment with the humanized monoclonal
antibody Trastuzumab [8–11]. Despite conﬁrmed overex-
pression of HER2, the current response rates to Trastuzumab
are less than 50% in the metastatic setting and many of
the patients that respond initially will eventually develop
resistance and subsequent recurrence of their disease [12–
14]. Standardization of both IHC and ISH methodologies
across laboratories remains a major problem [15]. because
of this approximately 20% of HER2 testing performed in the
ﬁeld may be inaccurate [16]. The ability to accurately and2 Pathology Research International
reproducibly quantify the level of HER2 protein expression
in tumors is critical to the appropriate selection of patients
for Trastuzumab and other HER2 targeted therapies.
Most laboratories in North America and Europe use IHC
to determine HER2 protein status, with equivocal category
results conﬁrmed by indirectly measuring HER2 gene ampli-
ﬁcation by Fluorescence In Situ Hybridization (FISH) or
more recently by the Chromogenic In Situ Hybridization
(CISH) assay [15, 17]. The College of American Pathology
Guidelines for HER2 testing algorithm includes testing all
newly diagnosed breast cancer patients. Patients with tumors
that are classiﬁed as >30% 3+ by IHC or FISH positive
(>2.2 HER2/CEP17 or >6 for noncorrected) are considered
HER2 positive and eligible for treatment with Trastuzumab,
while those that are IHC 2+ should be further conﬁrmed
by FISH testing [15, 18]. If the tumors that were originally
c a t e g o r i z e da sI H C2 +a r ec o n ﬁ r m e dt ob eF I S Hp o s i t i v e
these patients become eligible for Trastuzumab treatment
[10, 18, 19]. These routine tests are subject to interlaboratory
variation in both the accuracy and reproducibility between
thesetwomethodswithageneralconcordanceratepublished
for many studies of approximately ∼80%–90% (excluding
IHC 2+ cases) for IHC and FISH, well below the 95%
threshold mandated by the new ASCO-CAP guidelines [20].
Furthermore, a recent study was undertaken to evaluate
concordance between local and central laboratory testing for
HER2 in breast cancer specimens from the North Central
Cancer Treatment Group, N9831 Intergroup Adjuvant Trial.
The results demonstrated that the concordance rate between
local and central laboratory HER2 testing was between
75%–82% depending on whether which IHC technique was
used [21]. It is therefore critical that new testing methods
that are less subjective and more quantitative, accurate,
and reproducible to improve our ability to appropriately
select patients for expensive HER2 targeted therapies. There
are two FDA approved tests for IHC, HercepTest (Dako,
Carpentaria, CA), and Pathway (Ventana Medical Systems
Inc, Tucson, AZ), both of which utilize a single antibody
format on standard thin section FFPE tumors and the results
are based on a subjective, semi-quantitative scale (0, 1+,
2+, 3+) requiring microscopic evaluation and scoring by a
board certiﬁed pathologist [21]. There are four tests that are
FDA approved for FISH/CISH testing, including PathVysion
(Vysis Inc, Downers Grove, IL), INFORM (Ventana Medical
Systems Inc.), HER2 FISH pharmDx (Dako), and the
SPoT-Light CISH kit (Invitrogen, Carlsbad, CA) [21, 22].
FISH/CISH testing is also semiquantitative and subject to
inter-laboratory diﬀerences accounting for the relatively low
(88%) concordance rates demonstrated between local and
central FISH testing [21]. Because of these statistics, there
can be a number of false positive and negative results
from the use of these methods resulting in the inappro-
priate and the cost-ineﬃcient treatment of patients with
Trastuzumab.
To address the need for better methodologies of HER2
testing, we have developed an assay that can quantitatively
measure HER2 protein levels as well as the functional
HER2:HER2 homodimers in FFPE breast tumor specimens.
The assay has been validated according to the standards
deﬁned by CLIA and is routinely performed in a CAP-
accredited clinical reference laboratory. The assays are based
on the VeraTag technology platform [23] which utilizes
a proximity-based release of a ﬂuorescent tag bound to
a speciﬁc antibody and the subsequent quantiﬁcation of
this tag by capillary electrophoresis. In the most common
format of the platform, the dual-antibody approach provides
signiﬁcantlyincreasedspeciﬁcityandsensitivitycomparedto
single antibody-based IHC methods. The method provides a
continuum of highly quantitative results that span the entire
dynamic range of HER2 protein expression from 0 to 3+ if
compared with conventional IHC scoring methods, thereby
providing a more accurate assessment of the HER2 status of
a patient tumor.
In addition to the quantitative advantage of the VeraTag
assay, results obtained with HERmark assay from a clinical
cohort of 237 metastatic breast cancer patients originally
classiﬁed by a combination of IHC and FISH, demonstrated
98% concordance for IHC positive and negative assay
values (excluding equivocals) [24] This is well within the
ASCO/CAP guidelines requiring laboratories to show at least
95% concordance with another validated test for negative
andpositiveassayvalues[15].Theoverallconcordanceofthe
recent HER2 mRNA testing included as part of the Oncotype
Dx report is 70%–78% when compared with central IHC
[25]. The concordance of HER2 mRNA measurements
with central FISH is higher (97%) but this makes sense
when considering that both are indirect measurements of
drug response. Taken together, this supports the need for
quantitative and reproducible measurements the actual drug
target rather than relying on indirect measurements such
as gene ampliﬁcation or mRNA levels or with subjective
quantitation by IHC. An additional advantage of the VeraTag
platform is the ability to quantitatively measure protein-
protein interactions and speciﬁcally one of the primary
activated or functional forms of the HER2 protein (homod-
imer/proximer)[23]andpotentiallythetruedrugtarget.The
HERmark assay is a quantitative assay that accurately and
reproducibly measures HER2 total and homodimer protein
expression on a continuum as opposed to the subjective
classiﬁcation criteria of the current FDA approved HER2
IHC protein assays and therefore may have the potential to
stratify patients quantitatively for response to Trastuzumab
as well as other targeted therapies that are making their way
into the clinic.
2.MaterialandMethods
2.1.Antibodies,IsotypeControls,PhotosensitizerMolecule,and
Illumination Buﬀer. Monoclonal antibodies Ab8 and Ab15
directed against the intracellular domain of HER2 were pur-
chased from Lab Vision (Fremont, CA). Mouse monoclonal
antihuman IgG1 isotype control antibodies, biotinylated
and unconjugated, were purchased from BD Biosciences
(Franklin Lakes, NJ). The ﬂuorescent reporter Pro11 was
synthesized and puriﬁed according to protocol described
earlier (US Patent 7,105,308). Antibody-ﬂuorescent tag andPathology Research International 3
antibody-biotin conjugates Ab8-Pro11, Ab8-biotin, Ab15-
biotin, and IgG1-Pro11 were conjugated and puriﬁed as
described previously [23]. Ab8-Pro11 and IgG1-Pro11 were
matched to have similar hapten ratios. After puriﬁcation,
all antibodies were stored in 1X PBS with 1mg/mL BSA
and 0.001% sodium azide (Sigma-Aldrich, St. Louis, MO).
Streptavidin-conjugated methylene blue (SA-MB: “photoac-
tivator molecule”) was synthesized and puriﬁed according
to the protocol described earlier (US Patent 7,105,308).
Illumination Buﬀer (IB) contained 3pM ﬂuorescein and 2
additional capillary electrophoresis (CE) mobility markers
in 0.01X PBS. The ﬂuorescein was used as a quantitation
standard.
2.2. Illuminator and Chiller Blocks, CE Instruments, and
Slide Scanner. Three LED array illuminators customized
with chiller blocks (Torrey Pine Scientiﬁc, San Diego,
CA) were used to release reporter tags. Three ABI 3130
genetic analyzer CE instruments equipped with 22cm arrays
(Applied Biosystems, Foster City, CA) were used to detect
VeraTags. An HP ScanJet 4890 ﬂatbed scanner was used
to create a digital image of hematoxylin and eosin (H &
E) stained slides. Section area (mm2) was measured using
ImageJ software as described previously [23].
2.3. Cell Lines, Tissues, Cell Culture, Fixation, Processing and
Paraﬃn Embedding. The following breast cancer cell lines
were obtained from the American Type Culture Collection
(ATCC,Manassas,VA):SkBR3,BT-20,MDA-MB-453,MCF-
7, MDA-MB-468, BT-474, MDA-MB-361, T47D, MDA-MB-
231, Zr75-1, and A431. One melanoma cell line was utilized
MDA-MB-435S [26]. A431, MDA-MB-231, MDA-MB-361,
MDA-MB-453, and MDA-MB-468 were maintained in
Dulbecco’s Modiﬁed Eagle Medium (DMEM). BT-474 and
MDA-MB-435S were maintained in Dulbecco’s Modiﬁed
Eagle Medium: Nutrient Mixture F12 (DMEM/F12). T47D
and Zr75-1 were maintained in RPMI Media 1640. MCF-7
cells were maintained in Minimum Essential Medium Alpha
(αMEM). BT-20 cells were maintained in Eagle’s Minimum
Essential Medium with Earle’s Balanced Salt Solution
(EMEM + EBSS). SkBR-3 was maintained in McCoy’s 5A
media. All of the media were supplemented with 10%
fetal bovine serum (FBS), 10mM penicillin-streptomycin,
and 10mM Glutamax. All media and supplements were
purchased from Invitrogen (Carlsbad, CA). All cell lines
were cultured in a 37
◦C humidiﬁed atmosphere containing
95% air and 5% CO2 and were split and media replenished
according to ATCC recommendations. Cells were screened
for Mycoplasma contamination using standard PCR
methods. Forty-six patient derived tumors were purchased
as frozen tumor sample or tumor blocks from Asterand
(Detroit, MI), William Bainbridge (Seattle, WA), or
Proteogenix (Costa Mesa, CA). Frozen breast tissues were
made into FFPE blocks as previously described [23]. Two
tumor tissues were used to test the eﬀect of interfering
substances by being embedded with pathologically veriﬁed
normal breast stroma and fat samples.
After the cell cultures reached appropriate conﬂuence,
the cells were harvested 10–18 hours after being refed with
theappropriatemedia.Mediawasremovedfromthe500cm2
plates and the cells were washed with 1X PBS. The 1X
PBS was aspirated and approximately 25mL of Richard-
Allan Pen-Fix Formalin Fixative (Thermo Fisher Scientiﬁc,
Waltham, MA) was added to the cells. Cells were scraped
and ﬁxed overnight at 4◦C. Cells were then processed into
FFPE blocks as previously described [23]. Cell lines and
tumor tissue FFPE blocks were cut at 7μma n d5 μm
thickness, respectively, using a Leica RM 2145 and 2155
Rotary Microtome (Leica Microsystems, Bannockburn, IL).
Sectionswereplacedonpositivelychargedglassslides(VWR,
WestChester,PA),airdriedfor30minutesduringthetimeof
cutting all the sections, and then baked at 60
◦C for 1.5 hours.
All slides were stored at 4◦C until assayed and generally used
within 3-4 weeks.
3.ELISA,Flow Cytometry,andIHC
L y s a t e sw e r ep r e p a r e df r o m5 0 0c m 2 plates at 80% conﬂu-
ency. Cells were collected by scraping and washed three
times with cold PBS. The resulting pellets were lysed
in buﬀer containing 1% Triton X-100, 50mM Tris, pH
7.5, 50mM NaF, 50mM β-glycerophophate, 100mM NaCl,
1mM Na3VO4, 100μgP e p s t a t i nA ,5 μmE D T A( S i g m a -
Aldrich, St. Louis, MO), and 1 complete mini protease
inhibitor tablet (Roche, Basel, Switzerland). After lysis the
samples were centrifuged for 20 minutes at 4◦C and the
supernatants were stored at −80
◦C. Protein content for
each lysate was determined against a standardized control
using the Pierce Protein Assay Kit (Thermo Fisher Scientiﬁc,
Waltham, MA). Determination of HER2 protein content
was performed with a commercially available quantitative
enzyme-linked immunosorbent assay (ELISA) kit (EMD
Biosciences, San Diego, CA) according to the manufacturer’s
protocol. Cell lysates were serially diluted and measured in
triplicate. Each lysate was tested on three diﬀerent days.
HER-2 protein levels were determined in nanogram per
milligram of total protein (Table 1). For ﬂow cytometry
analysis, cells were harvested by trypsinization and counted.
5 × 105 cells were placed in a 96 well plate and labeled
with biotinylated primary monoclonal mouse antihuman
ErbB2 Ab4 (Lab Vision, Fremont, CA) at a concentration
of 4μg/ml in 100μl total volume. Isotype controls were
run using mouse IgG1 (BD Biosciences, Franklin Lakes,
NJ). The cells were incubated with antibody on ice for 45
minutes.Postincubation,thecellswerewashedtwicewith1X
PBS, followed by labeling with R-Phycoerythrin (PE)-Avidin
(Invitrogen, Carlsbad, CA) at 2μg/ml for 30 minutes on ice.
T h el a b e l e dc e l l sw e r ew a s h e dw i t h1 XP B St w i c ea n dﬁ x e d
with 1% paraformaldehyde in 1X PBS. FACS analysis was
performed on a FACSCalibur cytometer (BD Biosciences,
San Jose, CA). PE ﬂuorescence intensity of labeled cells was
determined on a FL2 (585/42nm band pass ﬁlter) detector.
The direct quantitation of the ﬂuorescence intensity of
samples in terms of number of molecules of ErbB2 receptors
was generated based on a calibrated standard curve using4 Pathology Research International
Table 1: Accuracy of cell line controls as measured by ﬂow cytometry, IHC, and ELISA. The majority of the cell lines used for accuracy studies
are of breast origin with the exception of MDA-MB-435 which has been shown to be of melanoma origin and A431, which is from an
epidermoid carcinoma of the vulva. All cell lines were grown in-house and FFPE blocks prepared on the same day as lysates prepared for
subsequent HER2 ELISA assay. The ﬂow cytometry was performed on the same day that the cells were ﬁxed and made into blocks. The
ELISA experiments represent an n = 3 experiments performed on separate days. The ﬂow cytometry assays were done in triplicate on the
same as described in materials and methods.
Cell Line HER2 IHC Score Flow Cytometry HER2 (receptors/cell) Flow Cytometry %CV ELISA [HER2] ng/mg ELISA %CV
BT474 3+ 499795.2 10.4 295.5 15.9
MDA MB 361 2/3+ 212456.0 1.9 65.7 7.4
BT-20 N/A 64,386 3.6 15.5 13.0
ZR-75-1 1+ 63,708 2.2 22.1 6.4
T47D 0/1+ 32303.1 8.2 16.3 11.3
A431 0 27343.1 0.8 23.3 2.3
MDA MB 231 0 11249.6 21.5 5.1 43.7
MDA MB 435 0 2420.5 6.1 2.9 70.7
MDA MB 468 0 10567.1 17.0 1.0 na
Quantum PE MESF Kit (Bangs Laboratories, Inc, Fishers,
IN). IHC was performed on Discovery XT automated
staining system (Ventana Medical Systems, Tucson, AZ)
using Ventana reagents according to the manufacturers
suggested protocol with slight modiﬁcations. Brieﬂy, slides
were labeled, deparaﬃnized and the Discovery XT was
programmed to perform cell conditioning using CC1 buﬀer.
After blocking, sections were incubated for 1 hour with
CB11 (Ventana cat # 760-2694), rinsed, then incubated with
secondary antibody for 32 minutes. After DAB detection, the
sections were counterstained with hematoxylin followed by
bluing reagent. The slides were removed, rinsed with PBST
and dehydrated using ethanol/xylene and coverslips applied
for microscopic evaluation.
4.HERmarkAssay
A batch of samples consists of 3 normalization controls,
spanning the dynamic range of the assay, 1 negative control,
1 accuracy control, and 15 patient tumor samples. FFPE
samples were loaded into a slide rack and placed in a
container ﬁlled with xylenes where they soaked for ﬁve
minutes, being agitated slightly. The samples were moved to
a fresh container of xylenes for an additional ﬁve minutes.
These steps were repeated with 100% reagent alcohol, 70%
ethanol, and ﬁnally deionized water. Immediately after
deparaﬃnization, the samples were placed in Diva Decloaker
(BioCare Medical, Concord, CA), a citrate-based buﬀer.
Heat-induced epitope retrieval was performed in a Decloak-
ingChamber(BioCareMedical,Concord),apressurecooker,
s e ta t9 5
◦C for 40 minutes. After cooling for 1 hour and
rinsing with water, a hydrophobic circle was drawn on the
slide to retain reagents in a deﬁned area. Sections were
blockedaspreviouslydescribed[23].Afterblocking,samples
were incubated with 4μg/mL of Ab8-Pro11 and 4μg/mL
Ab15-biotin for the H2T assay and 2μg/mL of Ab8-Pro11
and 2μg/mL Ab8-Biotin for the H2D assay overnight in a
humidiﬁed chamber at 4◦C. Post incubation, samples were
rinsed and incubated with Strepavidin-methylene blue (SA-
MB) as previously described [23]. Illumination buﬀer (IB)
was added to samples and slides were transferred to the
illuminator/chiller block. VeraTag Reporters were released
at approximately 4◦C as previously described [23]. Post
illumination, slides were removed from the chiller-block
and incubated in a humidiﬁed chamber at RT for 1 hour.
Samples were collected from the slides and reduced in
a ﬁnal concentration of 5ng/mL of sodium borohydride.
Subsequently, samples were diluted 1:5 and both neat and
diluted samples were separated and detected on an ABI 3130
capillary electrophoresis (CE) instrument. The injection
parameterswere6kV ,100sat30
◦Cand6kV ,50sat30
◦C,for
the H2D and H2T assays, respectively. Upon completion of
theHERmarkassay,sampleswereimmediatelyH&Estained
using standard protocols and reagents. A board certiﬁed
pathologist using standard criteria for invasive carcinoma
determined and circled the tumor area. Circled slides were
scanned and tumor area was calculated using the digital
imageofthesample.Theprogramusedtoquantifytheimage
was Image-Pro Plus version 6.0.0.260 (Media Cybernetics,
Inc.; Bethesda, MD).
5.DataAnalysis
Data analysis was performed as previously described [23].
In brief, signals from two concomitantly run CE markers
are used to demarcate the relevant region of the electro-
pherogram and to locate the assay-speciﬁc peaks from the
VeraTag reporters. Once identiﬁed, the signal intensity is
calculated for each VeraTag reporter as the peak height
integrated over the peak elution time. The VeraTag peak area
is then normalized to the peak area of the internal standard
ﬂuorescein, resulting in the relative peak area (RPA), which
is proportional to the concentration of the HER2 analyte
being measured. The RPA is then normalized to volume of
illumination buﬀer (IB) and tumor area (mm2)( T A )u s i n g
this calculation: RPA∗IB/TA.Pathology Research International 5
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Figure 1: Conﬁguration of the H2T and H2D assay. (a) Conﬁguration of the HER2 total assay consists of two antibodies speciﬁc to unique
epitopes on the c-terminus of the HER2 protein. One antibody (Ab-1) is conjugated to a VeraTag molecule (V) and the other is conjugated
to biotin (Ab-2). The photosensitizer molecule (PM) brings the strepavidin-methylene blue in close proximity to the antibodies. (b)
Conﬁguration of the H2D assay consists of one antibody that is speciﬁc for a unique epitope on the HER2 protein. The same antibody
is conjugated either to a VeraTag (V; Ab-1) or to biotin (Ab-1). The photosensitizer molecule (PM) brings the strepavidin-methylene blue in
close proximity to the antibodies.
Finally, reported values were adjusted to reﬂect batch-to-
batch trending in assay performance. Controls and samples
were normalized by multiplying their adjusted RPA with
the calculated Batch Normalization Factor (BNF). Adjusted
RPAs of the controls within a batch were compared to
reference values. A nonlinear regression analysis on the
paired data was performed and a BNF determined for
each batch. Separate BNFs were determined for the released
peak and the converted peak. Each adjusted RPA value was
multiplied by the respective BNF to obtain a normalized
RPA value. Because this normalized RPA value was unit-
less by deﬁnition, its value was referred to in VeraTag units.
All reportable normalized values for both peaks for a given
sample were averaged to determine a ﬁnal value for that
sample.
An algorithm was generated so that individual data
points within each validation parameter could be compared
in a pairwise fashion. Because a single patient sample is run
for each of the H2T and H2D assays, performing pairwise
comparisons allows for a high degree of conﬁdence in that
single measurement.
6. Results
6.1. Conﬁguration of the H2T and H2D Assays. The prin-
ciples of the VeraTag technology have been published
elsewhere [23]. In brief, the HER2 total assay conﬁguration
(Figure 1(a)) consists of a VeraTag reporter conjugated to
a speciﬁc antibody (Ab-1) that binds a distinct epitope
of HER2, while biotin is conjugated to a second antibody
(Ab-2) that recognizes a second unique HER2 epitope. In
a subsequent reaction, a secondary streptavidin-methylene
blue conjugate is bound to the biotin-antibody complex to
form a photosensitizer molecule (PM). Upon photoactiva-
tion, the PM allows the generation of reactive oxygen that
subsequently cleaves the most proximal VeraTag reporter,
yielding a released ﬂuorescent molecule with a distinct
charge to mass ratio. The ﬂuorescent molecule is accurately
quantiﬁed using standard capillary electrophoresis (ABI
3130). The H2D assay is similar in conﬁguration with the
exception that the biotin is conjugated to the same antibody
(Ab1) that recognizes the same epitope as the VeraTag
reporter antibody conjugate (Ab1) as shown in Figure 1(b).
6.2. HERmark Assay Workﬂow. The HERmark assay work-
ﬂowhasbeendescribedindetailintheMaterialandMethods
and is depicted schematically in Figure 2. In brief, the FFPE
tumor tissues are subjected to deparaﬃnization/rehydration,
antigen retrieval, and the conjugated antibodies are then
addedandincubatedovernight.Thefollowingdaythetissues
are processed as described in Materials and Methods and
then illuminated on a chiller block for two hours. Following
illumination, the VeraTag reporters are collected from the
tumor specimens and run on capillary electrophoresis and
quantiﬁed using proprietary informer software. The sections
are then H & E stained and the invasive tumor area identiﬁed
by a board certiﬁed pathologist and quantiﬁed using an
imageanalysissystemasdescribedinMaterialsandMethods.
Tumors that are morphologically more than 50% DCIS are
excluded from the analysis. The tumor area is calculated
by the identiﬁcation and circling of the invasive tumor by
a board certiﬁed pathologist and subsequently quantifying
this area using an image analysis system as described in
Materials and Methods. The ﬁnal VeraTag data reported is
normalized to the actual tumor area and the entire batch is
normalized using cell line controls that have been previously
characterized with expected values (data not shown).
6.3. Accuracy (Comparison with Known Reference Methods).
The accuracy of the H2T assay was assessed by testing
multiple independent cell lines that were previously charac-
terized in the literature or in house using cross-validating6 Pathology Research International
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Figure 2: HERmark Assay Workﬂow. Deparaﬃn/rehydration, antigen retrieval, and overnight antibody incubation steps are performed on
Day 1. On day 2, the tumor tissue is incubated with the photosensitizer molecule and illuminated to release VeraTags. VeraTags are collected
and separated on capillary electrophoresis and the tumors are H & E stained, tumor area identiﬁed and circled and the ﬁnal sample and
batch normalized data is typically available within a 7 day turnaround time.
technologies. HER2 total levels in human cancer cell lines
have been published using a variety of analytical techniques,
including Western Blot data [27] and ELISA [28]. Minor
discrepancies between diﬀerent published datasets are often
attributed to minor changes in how the cells were cultured
and harvested and/or the assay used to generate the data.
For these reasons, Monogram generated internal datasets
on HER2 total levels by both ELISA and ﬂow cytometry
(Table 1). The cell lines chosen spanned the range of known
HER2expressionfromHER2negativetoHER23+asdeﬁned
by subjective criteria for IHC [29]. For the H2T assay,
accuracy was assessed by measuring the HER2 total levels in
seven cell lines (BT474, MDA-MB-361, T47D, A431, MDA-
MB-231, MDA-MB-435 and MDA-MB-468) selected to span
the approximate dynamic range of the assay. Two batches
were required to run all 21 samples (3 samples for each
of 7 cell lines). Three samples of each of the following
four cell lines were run in one batch: BT474, MDA-MB-
361, T47D, and A431. The second batch contained the
three remaining cell lines (MDA-MB-231, MDA-MB-435,
and MDA-MB-468) as well as repeated samples of A431.
100% (21/21 pairwise comparisons) of overall accuracy
results matched expected results (Figure 3(a)) in that no
overlap was observed between signal levels for any of the
seven cell line samples, that is, each cell line separated
completely from its nearest neighbor(s). For the H2D assay,
no independent measurement of homodimers is currently
available, so results were compared to in-house previous
H2D assay measurements as well as independent HER2 total
measurements [23]. Samples from six diﬀerent cell lines
were each tested in triplicate (BT-474, MDA-MB-361, BT-
20, ZR-75-1, T47D, and MDA-MB-468) over two separate
batches and 100% (18/18 pairwise comparisons) of the
resultsmatchedpredictedH2Dlevels(Figure 3(b))withrank
order preservation and no overlap of values. These results
suggest that the data from the H2T and H2D assays are
comparable to results from ELISA and ﬂow cytometry assays
performed concurrently as well as published results [27].
6.4.Precision(Intra-AssayVariability)OftheHERmarkAssay.
Assay precision was evaluated by determining the variability
within a single assay or batch. Measurements were done by
testing two independent cell lines spanning the high and low
end of the assay dynamic range with 15 replicates per cell
line per batch (MDA-MB-453 and MCF-7 for H2T; SKBR3
and MDA-MB-453 for H2D) and analyzing the results using
pairwise comparisons. For the H2T assay, 100% (210/210)
pairwise comparisons were within 1.7-fold and >95% of the
pairwise comparisons were within 1.45-fold (Figure 4). For
the H2D assay 100% (210/210) of the pairwise comparisons
were within 2.3-fold and >95% of the pairwise comparisons
were within 1.65-fold (Figure 4). The %CV for precision of
all data in the H2T assay was 14.9% (MDA-MB-453) and
12.5% (MCF-7). The %CV for precision of 100% data in the
H2D assay was 14% (SKBR3) and 21% (MDA-MB-453).
6.5. Reproducibility (Interassay Variability) of the H2T and
H2D Assay. Assay reproducibility was evaluated by deter-
miningthevariabilitybetweenbatches.Theinterassayrepro-
ducibility was evaluated over numerous parameters typically
encountered in the clinical reference lab, including at least
two operators, multiple instruments (illuminators/chiller
blocks, scanners and capillary electrophoresis instruments),
two lots of critical reagents, two lots of cell line controls, and
multiple days/weeks. Samples consisted of a combination of
45 patient-derived FFPE samples (sample IDs not shown)
and 12 cell line samples as shown in (Table 2). Samples werePathology Research International 7
0.1
1
10
100
1000
B
T
4
7
4
M
D
A
-
M
B
-
3
6
1
T
4
7
D
A
4
3
1
M
D
A
-
M
B
-
2
3
1
M
D
A
-
M
B
-
4
3
5
M
D
A
-
M
B
-
4
6
8
N
o
r
m
a
l
i
s
e
d
H
2
T
(a)
0.1
1
10
100
1000
B
T
4
7
4
M
D
A
M
B
3
6
1
B
T
2
0
Z
R
7
5
-
1
T
4
7
D
M
D
A
-
M
B
-
4
6
8
N
o
r
m
a
l
i
s
e
d
H
2
D
(b)
Figure 3: Accuracy of the H2T and H2D assays. Seven ((a); H2T) and six ((b); H2D) diﬀerent cell lines with varying levels of HER2 total
protein, as measured by in house ELISA and ﬂow cytometry, were run in the H2T assay in two separate batches. All signals showed correct
rank order and accuracy based on ELISA and ﬂow cytometry comparisons.
1
10
100
1000
M
D
A
-
M
B
-
4
5
3
(
H
2
T
)
M
C
F
-
7
(
H
2
T
)
S
K
B
R
3
(
H
2
D
)
M
D
A
-
M
B
-
4
5
3
(
H
2
D
)
N
o
r
m
a
l
i
s
e
d
H
2
T
o
r
H
2
D
Figure 4: Precision of the HERmark assay. Fifteen replicates of each
of 2 diﬀerent cell lines spanning the dynamic range of the H2T and
H2D assays were run in one batch for each assay to determine intra-
assay variability. 95% of the values in the H2T and H2D assay are
within 1.45-fold and 1.65-fold, respectively.
grouped into three tumor sets (TS): A, B, and C (TSA, TSB,
TSC) and one cell line panel (CLP). Results were compared
pairwise after each sample was run in separate batches. For
the H2T assay, each sample set was run in two diﬀerent
batches and, for the the H2D assay, each sample set was
run in three diﬀerent batches. Of the reportable values, 96%
of the pairwise comparisons were within 2-fold in the H2T
assay (Figure 5(a)). For the H2D assay, 95% of the pairwise
comparisons were within 2.2-fold (Figure 5(b)).
Table 2: Summary of the cancer cell lines (A) used in the validation
of the HERmark assay.
Cell Line Source Source ID
SKBR3 ATCC
(1) HTB-30
BT20 ATCC HTB-19
MDA-MB-453 ATCC HTB-131
MCF7 ATCC HTB-22
MDA-MB-468 ATCC HTB-132
BT474 ATCC HTB-20
MDA-MB-361 ATCC HTB-27
T47D ATCC HTB-133
MDA-MB-231 ATCC HTB-26
MDA-MB-435 ATCC HTB-129
ZR-75-1 ATCC CRL-1500
A431 ATCC CRL-1555
(1)ATCC= American Type Culture Collection.
6.6. Sensitivity of the H2T and H2D Assays. For the H2T
assay, two cell lines (i.e., MDA-MB-435 and MDA-MB-468)
wereselectedforsensitivityandthesamplesruninonebatch.
ThebatchconsistedofsixsamplesofMDA-MB-468andnine
samples of MDA-MB-435, yielding 54 potential pairwise
comparisons. MDA-MB-468 has little or no HER2, while
MDA-MB-435 has low signal levels, less than the lowest assay
control, MCF7 [27, 28] as well as in house data (not shown).
100% (54/54) of the pairwise comparisons were within
the stated acceptance criteria that all MDA-MB-435 values
are greater than MDA-MB-468 values. Results are detailed
in Figure 6(a), sorted from lowest signal to highest signal.
Because the largest MDA-MB-468 signal (1.46) was less than
the smallest MDA-MB-435 signal (3.59), detailed pairwise8 Pathology Research International
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Figure 5: Reproducibility of the H2T and the H2D assay. Run 1 and run 2 represent a combination of 45 breast cancer tumors and 11 cancer
cell lines assayed in two diﬀerent batches. The batches were run to incorporate the following comparisons: separation by 10 days, multiple
illuminators, chiller blocks, pressure cookers, and capillary electrophoresis instrument, two runs with separate lots of critical control slide
reagents and critical liquid reagents. Pairwise comparisons were made on each of the separate runs. For the H2T assay 2 separate runs (a)
were performed. For the H2D assay 3 separate runs were performed; results from a typical pairwise comparison are shown in (b).
comparison was unnecessary. For the H2D assay, two cell
lines (T47D and MDA-MB-468) were selected for sensitivity
and the samples were run in one batch. The batch consisted
of six samples of MDA-MB-468 and nine samples of T47D,
yielding 54 pairwise comparisons. MDA-MB-468 has little
or no HER2, while T47D has signal levels comparable to
the low control, MCF7 [27, 28], and in, house data, (not
shown). 100% (54/54) of the pairwise comparisons were
within the stated acceptance criteria (T47D > MDA-MB-
468). Results are detailed in Figure 6(b),s o r t e df r o ml o w e s t
signal to highest signal. Since the largest MDA-MB-468
signal (0.82) was less than the smallest T47D signal (0.97),
detailed pairwise comparison was unnecessary.
6.7. Linearity of the H2T and H2D Assays. The ability of
the capillary electrophoresis instrument to evaluate patient
samples over a wide range of H2T and H2D levels was
demonstrated using the HER2 positive cell line control
BT474. Samples were processed according to standard pro-
cedures through illumination and conversion as described
in Materials and Methods. Following sample dilution, three
replicate plates were made and then one plate each was run
on three independent capillary electrophoresis instruments.
Final reportable values were multiplied by the corresponding
dilution factor and then compared in pairwise fashion.
Two types of dilutions were performed: serial dilution and
nonserial dilution. Serial dilutions were performed to cover
the dynamic range of the assay from the highest reportable
signal (undiluted) to the lowest reportable signal. Non-serial
dilutionswereperformedtocomparefromhightolowsignal
in a single dilution. Pairwise comparisons of concentration-
corrected signals from the serial dilutions and non-serial
dilutions from all three capillary electrophoresis instruments
were analyzed in aggregate.
For the H2T 95% (303/319) of the pairwise comparisons
were within 1.4-fold (data not shown). For the H2D assay,
95% (183/193) of the pairwise comparisons were within 1.8-
fold (data not shown).
6.8. Sample FFPE Section Size Validation Testing and Results.
The ability of the assay to evaluate patient samples over a
wide range of H2T and H2D levels and to conﬁrm that the
reportable normalized value is independent of section size
was demonstrated using HER2 positive cell line controls,
selected to cover the dynamic range of the assay. Sample
s l i d e sf r o mS K B R 3 ,M D A - M B - 3 6 1a n dB T 2 0c e l ll i n e sw e r e
each subsectioned to the approximate following sizes: 1
(full), 0.5 (half), 0.25 (quarter), and 0.125. The approximate
size of a full section was 50mm2. The slides were prepared
by cutting away material from a full slide. For each cell
line, two samples of each size were run using in the H2T
and H2D assay, except for SKBR3 full size, which was run
only once (in each assay) due to batch size constraints.
Final reportable values (i.e., after area normalization) were
compared in pairwise fashion.
For the H2T assays, 100% of the pairwise comparisons
were within 2-fold and 95.8% of the pairwise comparisons
werewithin1.7-fold(Figure 7(a)).FortheH2Dassay,95%of
the pairwise comparisons were within 2.2-fold (Figure 7(b)).
6.9. Speciﬁcity. Assay speciﬁcity was demonstrated in a series
of experiments designed to assess the frequency of false
positive results from experiments using isotype control
antibodies as well as false negative results due to the presence
ofcommonlyencounteredinterferingsubstances.45patient-
derived tumor samples (data not shown) and 12 cell line
samples (Table 2) were run using the H2T and isotype
control antibodies. Isotype control antibodies were matched
to the constant regions of the respective HER2 antibodies.
For the HER2 Ab8-Pro11, the matched isotype control was
IgG1-Pro11. For the HER2 Ab15-biotin, the matched isotype
control was also IgG1-biotin. Signal generated from thesePathology Research International 9
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Figure 6: Sensitivity of the H2T and H2D assays. (a) To assess the sensitivity of the H2T assay 2 diﬀerent cell lines were utilized, a negative
HER2 total protein cell line, MDA-MB-468, and a low HER2 receptor/cell MDA-MB-435 (IHC score of 0, see Table 2). (b) Sensitivity of the
H2D assay was assessed using the negative cell line MDA-MB-468 and the low receptor cell lineT47D (IHC score of 0/1+, see Table 2).
reactions is not antigen speciﬁc, and represents nonspeciﬁc
background. Samples were run in each of the following three
formats for H2T and each format was run in a separate
batch: Format 1: HER2 Ab8-Pro11/HER2 Ab15-biotin (assay
speciﬁc format), Format 2: HER2 Ab8-Pro11/IgG1-biotin,
and Format 3: IgG1-Pro11/HER2 Ab15-biotin. For H2D, the
formats were: Format 1: HER2 Ab8-pro11/HER2 Ab8-biotin
(assay speciﬁc format), Format 2: HER2 Ab8-pro11/IgG1-
biotin, and Format 3: IgG1-pro11/HER2 Ab8-biotin. Sample
results from each IgG1 format (Format 2 and Format 3) were
compared to the negative control, MDA-MB-468, present
in each batch. Samples results were also compared to the
respective actual H2T or H2D signal. The results of the
H2T assay demonstrated that 100% (112/112) of the results
passed this criterion (either within 2-fold of the MDA-MB-
468 background signal or less than or equal to 10% of the
correspondingH2Tsignal).ResultsareshowninFigure 8(a).
In the H2D assay, 99% (108/109) of the comparisons were
within the stated acceptance criteria (either within 3-fold of
the MDA-MB-468 background signal or less than or equal to
20% of the corresponding H2D signal). Results are shown in
Figure 8(b).
6.10. Interfering Substances Validation Testing and Results.
To analyze the eﬀect of interfering substances on the H2T
signal, two tumor samples positive for HER2 878/1006/496:
1006—high HER2; 272/31274B2/884: 31274B2—low HER2)
werere-embeddedwithpotentialinterferingsubstancesfrom
normal stroma tissue (496 and 884) and normal fat tissue
(878 and 272). The blocks were then cut into slides and
a subset of slides was sub-sectioned to remove the normal10 Pathology Research International
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Figure 7: Section size linearity of the H2T and H2D assays. (a) Cell line controls with varying levels of H2T (a) and H2D (b) were sub-
sectioned and then run in the HERmark assay to determine linearity of the measurements with respect to section size. Normalized values
(y-axis) show the ﬁnal signals that have been corrected for size. 95.8% of the pairwise comparisons were within 1.7-fold in the H2T assay
and 95% of the pairwise comparisons were with 2.2-fold for the H2D assay.
stromaandnormalfat(tumoronly:1006or31274B2).These
slides were then run with the corresponding whole (i.e.,
not sub-sectioned) re-embedded slides in the H2T assay. A
pairwise comparison of ﬁnal results was then obtained. For
878/1006/496, four samples of tumor only and four samples
of tumor/stroma/fat were run in one batch, resulting in 16
pairwise comparisons. For 272/31274B2/884, six samples of
tumor only and 9 samples of tumor/stroma/fat were run in
one batch, resulting in 54 pairwise comparisons. A total of
70 pairwise comparisons were obtained and 100% (70/70) of
the pairwise comparisons were within the stated acceptance
criteria (2.5-fold). Further, 97% of the pairwise comparisons
were within 2-fold, and 95% of the pairwise comparisons
were within 1.9-fold. Results are detailed in Figure 9(a).
To analyze the aﬀect of interfering substances on the
H2D signal, the same tumor sample as above was used
(878/1006/496) and the blocks cut into slides and a subset of
slides was sub-sectioned to remove the normal stroma and
normal fat. These slides were run with the corresponding
whole (i.e., not sub-sectioned) re-embedded slides in the
H2D assay. A pairwise comparison of ﬁnal results was then
obtained. Seven samples of tumor only and eight samples
of tumor/stroma/fat were run in one batch, resulting in
56 pairwise comparisons. 100% (56/56) of the pairwise
comparisons were within the stated acceptance criteria (3-
fold).100%ofthepairwisecomparisonswerewithin2.4-fold
and 95% of the pairwise comparisons were within 2-fold.
Results are shown in Figure 9(b).
6.11. Validation Summary. The summary of the HERmark
CLIA validation results is shown in Table 3. For each assay,
H2T and H2D, several parameters of assay performance
were tested including accuracy, precision, reproducibility,
sensitivity, linearity, and speciﬁcity. The percentage of results
passing the validation is based on a 2-fold cutoﬀ where
applicable. For the H2D assay, there are two parameters,
reproducibility and FFPE section size linearity that did not
pass the 95% 2-fold cutoﬀs and but were 91.8% and 92.2%,
respectively. Diﬀerences in the amount of H2D in the cell
relative to H2T and/or the diﬀerences between the two assay
formats may account for the decreased performance of the
H2D assay relative to the H2T. In addition, the measurement
on smaller section sizes may result in variability outside the
linear range of the assay.Pathology Research International 11
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Figure 8: Isotype control speciﬁcity of H2T and H2D assays. All 44 tumors and 11 cell lines were tested in the regular H2T assay. Slide samples
from adjacent sections were also run in an H2T assay where the anti-HER2-pro11 antibody conjugate was replaced with an IgG1-pro11
conjugate(“IgG1-pro11”)orwheretheanti-HER2-biotinantibodyconjugatewasreplacedwithanIgG1-biotinconjugate(“IgG1-biotin”).(a)
is a graphical representation of the non-speciﬁc contribution of signal in the H2T assay whereas (b) represents the non-speciﬁc contribution
of the signal in the H2D assay.
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Figure 9: Tissue Speciﬁcity testing of the H2T and H2D assays. Tissue speciﬁcity was determined by measuring the H2T signal (a) or H2D
signal (b) generated by the comparison of tumor tissue alone and with tumor tissue in addition to normal fat and stroma. 1006 = breast
tumor; 878-1006-496 = breast tumor embedded with stroma and fat (a, b). 31274B2 = tumor; 272-31274B2-884 = breast tumor embedded
with stroma and fat (a).
7. Discussion
We described the analytical validation of the HERmark assay
thataccurately,reproducibly,andsensitively,measuresHER2
total protein as well as HER2:HER2 homodimers in FFPE
specimens from breast tumor specimens and is based on the
VeraTag technology. The relationship between quantitative
HER2 expression as measured by HERmark and clinical
outcome of metastatic breast cancer patients was previously
reportedanddescribesacontinuumofHER2expressionthat12 Pathology Research International
Table 3: H2T and H2D assay validation summary. The parameters tested in the validation of the HERmark assay are summarized and the
percentage passing is based on a 2-fold cutoﬀ. NA indicates that a detailed pairwise comparison was not necessary and so therefore the 2-fold
cutoﬀ was not applicable. 195th percentile at 2.2 fold cutoﬀ.
Parameter H2T Summary % Within Two-fold Cutoﬀ H2D Summary % Within Two-fold Cutoﬀ
Accuracy Pass NA (100) Pass NA (100)
Sensitivity Pass NA (100) Pass NA (100)
Precision Pass 100 Pass 99.5
Reproducibility Pass 96.4 Pass 91.81
Linearity: CE Pass 99.7 Pass 99%
Linearity: Section Size Pass 100 Pass 92.21
Speciﬁcity: Triple Re-embed Pass 97.1 Pass 94.6
Speciﬁcity: Isotype Pass NA (100) Pass NA (99.1)
correlates with outcome following trastuzumab treatment.
[30, 31]When HERmark measurements are compared retro-
spectively with IHC and ISH testing on a set of metastatic
breast cancer tumors originally classiﬁed as HER2 positive
and eligible for Trastuzumab treatment, a subset (∼13%)
was subsequently reclassiﬁed [32]. These patients experi-
enced times-to-progression (TTP) following trastuzumab
treatment, that were indistinguishable from those of patients
classiﬁed as central FISH-negative, and signiﬁcantly shorter
TTP than similar FISH- positive patients who also showed
over-expression of HER2 by HERmark. When samples were
compared retrospectively in larger adjuvant clinical trial
(FinHer) originally selected for HER2 status by a combina-
tion of local IHC and central CISH, ∼13%–23% of patients
were reclassiﬁed by HERmark depending on the comparison
(local or central IHC, or both central IHC and CISH)
[33]. Excluding the equivocal cases in this study, HERmark
demonstrated 97% concordance with IHC for positive and
negative assay values. We have previously established a
clinical cut-oﬀ whereby patients above a certain threshold
of HER2 protein, as determined by HERmark, respond
better in time to progression to Trastuzumab treatment
than those below this cut-oﬀ determined by positional
scanning [32]. Interestingly, this clinical cutoﬀ falls within
the HERmark equivocal zone which is deﬁned by the 95%
conﬁdence of this measurement as compared to ∼1090
breast cancer tissue specimens tested by reference methods
(IHC/ISH). It is worthwhile to note that the HERmark
equivocal category encompasses a relative narrow range (∼
0.2log) within the wide dynamic range (∼2-3log) of HER2
distribution, while the semi-quantitative IHC 2+ category
(consideredequivocal)may include tumors with widerrange
of HER2 expression. The current IHC testing is based on
a subjective, semi-quantitative scale (0, 1+, 2+, and 3+)
requiringmicroscopicevaluationbyaboardcertiﬁedpathol-
ogist. Standardization of such a method across laboratories
requires robust methods to ensure that there is consistency
in the testing method as well as the scoring based on a
nonautomated system [21]. The HERmark assay provides
a continuous, quantitative, and reproducible measurement
for H2T and H2D over a dynamic range of ∼3logs and
∼2logs, respectively. This allows the accurate separation of
cell line controls that were originally classiﬁed as 2+ to 3+
into a continuum that spans a HER2 protein levels 5–10-
fold as measured by HERmark. These results agree quite
well with in-house measurements using low throughput
quantitative methods such as ﬂow cytometry and ELISA
and testing on the same cell line preparations as used for
the FFPE blocks. We have also demonstrated previously
that H2T measurement in a set of 170 tumors correlates
well with in-house IHC measurements [23]. Furthermore,
the corresponding histoscores (H-score), on this subset of
tumors,asmeasuredbyHER2IHC,demonstrateaplateauin
the IHC 3+ category and the inability to accurately stratify at
high levels of HER2 protein, whereas measurement by H2T
demonstrates >10-fold diﬀerence in dynamic range [23].
There is no standard way to measure HER2 homodimer
levels but it has been demonstrated previously that over-
expression of HER2 protein expression may be required to
transform a cell line in vitro [2]. Biologically a diﬀerence
in HER2 receptor levels in the range of 5–10-fold may
have signiﬁcant impact on patient response to Trastuzumab
[34]. This is especially important when considering the low-
response rates and emerging evidence that levels of p95, the
truncated form of full-length HER2, correlate with higher
levels of H2T [34]. In addition to the extension of the
dynamic range at the higher end, the HERmark assay is
able to accurately distinguish a set of cell line controls
classiﬁed by IHC as 0 to 1+ but spanning a ∼20 fold
dynamic range from a negative control cell line, MDA-
MB-468 that has no detectable HER2 protein expression
as measured by ELISA. This diﬀerence corresponds to a
r a n g eo fH E R 2t o t a lr e c e p t o r sp e rc e l lf r o ml o w / n e g a t i v e
up to ∼30,000 as determined by ﬂow cytometry. We have
demonstrated that the sensitivity of the H2T measurement is
equivalent to 2500 receptors/cell whereas conventional IHC
is typically 7–10 times less sensitive. Therefore, when the
cell line MDA-MB-435 is measured by IHC the result is
a classiﬁcation of 0 or negative (in house data). Recently,
adjuvant clinical trials have indicated that even patients that
are not overexpressing HER2 as measured by IHC and FISH,
may respond to Trastuzumab treatment, indicating that
accurate and sensitive measurements at the lower end of the
dynamic range may also be clinically relevant [16]. Similarly,
the quantitative measurement of low levels of HER2 may
be clinically relevant for other types of solid tumors as inPathology Research International 13
the case of Barrett’s esophagus-associated adenocarcinoma
cancer[35].OtherquantitativemeasurementsofHERfamily
proteins (EGFR and HER2) have been developed based
on the AQUA technology, however, in the case of HER2
it has been shown that two diﬀerent concentrations of
HER2 antibody are required to accurately quantify the HER2
levels depending on whether the measurements are made
in the upper range or lower dynamic range of expression
[36]. Applying this to routine practice could be quite
cumbersome and may increase the subjective nature of the
HER2 protein measurement. The HERmark assay consists
of cell line controls that span the entire dynamic range of
HER2 protein expression and are used to control for batch
to batch variability, allowing comparisons to be made over
time between clinical samples. Since a patient sample is
measured only once, it was important to rigorously test the
intra- and interassay variability to determine the conﬁdence
level surrounding this measurement. Precision experiments
demonstrated that if a patient sample is measured multiple
times within a batch, there is a 95% probability that the
H2T value will be within 1.45-fold and that the H2D value
will be within 1.65-fold. The precision was determined using
cell lines that span above and below the clinical cutoﬀ for
response to Trastuzumab in a test cohort as decribed above.
With a dynamic range of 2-3logs, the potential of classifying
a patient as a false positive or negative theoretically should
be greatly reduced; however, there will be some ambiguity
in the measurement at or around the clinical cutoﬀ based
on the analytical performance of the assay. This analytical
performance applies to all methods of HER2 testing includ-
ing IHC, ISH, and mRNA measurements and may explain
whythereis so much reclassiﬁcation whenstandard testing is
compared to HERmark, especially in the equivocal category.
Inter assay reproducibility was evaluated under diﬀerent
parameters typically encountered in a clinical laboratory
includingdiﬀerentoperators,multipleinstruments,diﬀerent
days and two lots of critical reagents. This also allows the
comparison of what might be typically associated when
samples are run in diﬀerent central labs as routinely done for
HER2 IHC and FISH testing for Trastuzumab inclusion. In
addition to good reproducibility the speciﬁcity of the assay is
increased due to the fact that the VeraTag technology relies
on the binding of two epitope-speciﬁc antibodies in close
proximity. Conventional IHC relies on a single antibody
a n dr e q u i r e sh i g hd e g r e eo fs p e c i ﬁ c i t yt h a ti sd i ﬃcult to
achieve with varying heterogeneity in tumor samples. Batch
normalization of the data allows for Meta analysis of clinical
studies and to validate potential clinical cutoﬀsa sw e l la st o
monitor assay performance over time. In general, a higher
concordance was observed between H2T by HERmark and
HER2 assessed by more stringent centraltesting as compared
with local HER2 testing by IHC in that the results were 97%
concordant overall (excluding equivocals) [37]. Further-
more, HERmark positive breast cancers were signiﬁcantly
associatedwithinvasiveductalcarcinoma,hightumorgrade,
estrogen/progesterone receptor negativity, and expression of
Ki67 [38]. Thus the quantitative HER2 measurement by
HERmark conﬁrms the known correlations between HER2
expression and clinical pathologic characteristics of breast
cancer. The use of a more accurate and quantitative HER2
measurement may allow better stratiﬁcation of patients for
response to HER2 targeted therapies as well as improve the
accuracy and sensitivity of the testing methodology.
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